https://aonn.digitellinc.com/p/cf/aonn-plus-2020-midyear-virtual-conference-6
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-wellstat-therapeutics-61
https://aonn.digitellinc.com/p/s/welcome-to-aonn-plus-midyear-virtual-conference-66
https://aonn.digitellinc.com/p/s/general-session-1-cancer-and-mental-health-lightening-the-load-for-patients-and-families-76
https://aonn.digitellinc.com/p/s/general-session-2-spread-the-word-early-detection-and-screening-saves-lives-86
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-eli-lilly-96
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-bristol-myers-squibb-101
https://aonn.digitellinc.com/p/s/general-session-3-vaping-the-new-epidemic-111
https://aonn.digitellinc.com/p/s/general-session-4-mechanisms-of-action-integrating-biosimilars-in-cancer-treatment-121
https://aonn.digitellinc.com/p/s/general-session-5-patient-navigation-and-covid-19-131
https://aonn.digitellinc.com/p/s/general-session-6-treatments-support-and-quality-of-life-for-patients-with-metastatic-disease-141
https://aonn.digitellinc.com/p/s/general-session-7-the-role-of-the-navigator-identifying-gaps-and-facilitating-improvements-in-patient-care-151
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-janssen-161
https://aonn.digitellinc.com/p/s/general-session-8-fertility-preservation-166
https://aonn.digitellinc.com/p/s/general-session-9-team-based-care-understanding-compassion-fatigue-and-burnout-amongst-nurse-and-patient-navigators-176
https://aonn.digitellinc.com/p/s/general-session-10-direct-to-consumer-dtc-genetic-testing-what-the-journals-report-how-the-media-covers-it-and-how-it-affected-patients-186
https://aonn.digitellinc.com/p/s/general-session-11-read-feel-create-heal-supporting-children-of-parents-with-cancer-closing-remarks-196
https://aonn.digitellinc.com/p/cf/aonn-plus-annual-2020-202
https://aonn.digitellinc.com/packages/22/view
https://aonn.digitellinc.com/p/s/preconference-workshop-genetics-and-genomics-bridge-344
https://aonn.digitellinc.com/p/s/preconference-workshop-financial-navigation-adapting-to-the-new-normal-changes-rt-covid-the-new-financial-landscape-349
https://aonn.digitellinc.com/p/s/preconference-workshop-seed-into-your-professional-development-and-strengthen-your-skills-presented-by-the-aonn-plus-leadership-council-354
https://aonn.digitellinc.com/p/s/preconference-workshop-motivational-interviewing-the-basics-359
https://aonn.digitellinc.com/p/s/welcome-and-opening-remarks-and-awards-non-ce-364
https://aonn.digitellinc.com/p/s/general-session-1-navigating-the-waters-of-telehealth-impact-on-the-practice-of-oncology-navigation-369
https://aonn.digitellinc.com/p/s/general-session-2-equipping-navigation-teams-for-metrics-implementation-374
https://aonn.digitellinc.com/p/s/general-session-3-beyond-efficacy-toxicity-and-cost-patients-define-cancer-care-value-in-the-united-states-379
https://aonn.digitellinc.com/p/s/new-orleans-virtual-walking-tour-non-ce-384
https://aonn.digitellinc.com/p/s/general-session-4-navigating-cancer-related-legal-issues-389
https://aonn.digitellinc.com/p/s/general-session-5-navigating-mental-health-and-cancer-whats-an-oncology-nurse-and-patient-navigator-to-do-394
https://aonn.digitellinc.com/p/s/industry-sponsored-session-dont-delay-act-now-urgent-treatment-of-early-onset-severe-toxicity-of-5-fu-or-capecitabine-non-ce-presentation-by-wellstat-399
https://aonn.digitellinc.com/p/s/navigating-the-renal-cell-carcinoma-patient-non-ce-404
https://aonn.digitellinc.com/p/s/industry-sponsored-session-multiple-myeloma-patient-journey-and-starter-kits-multi-stakeholder-panel-non-ce-presentation-by-bristol-myers-squibb-409
https://aonn.digitellinc.com/p/s/keynote-session-understanding-vicarious-trauma-and-its-path-to-resilience-414
https://aonn.digitellinc.com/p/s/visit-the-exhibit-and-poster-hall-419
https://aonn.digitellinc.com/p/s/product-theater-1-intervening-with-jakafi-r-ruxolitinib-to-achieve-durable-count-control-real-world-patient-case-discussion-focus-on-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hy-424
https://aonn.digitellinc.com/p/s/product-theater-2-a-cdk-4-and-6-inhibitor-with-overall-survival-data-for-women-with-hr-plus-her2-metastatic-breast-cancer-including-those-likely-to-do-worse-non-ce-presentation-by-lilly-oncology-429
https://aonn.digitellinc.com/p/s/industry-sponsored-session-reduce-the-risk-of-recurrence-in-her2-plus-breast-cancer-proactive-treatment-management-strategies-non-ce-presentation-by-puma-biotechnology-434
https://aonn.digitellinc.com/p/s/general-session-6-health-disparities-in-rural-communities-439
https://aonn.digitellinc.com/p/s/breakout-session-1-aonn-plus-poster-winner-presentations-categories-i-iv-444
https://aonn.digitellinc.com/p/s/breakout-session-2-fertility-preservation-449
https://aonn.digitellinc.com/p/s/breakout-session-3-multisite-navigation-454
https://aonn.digitellinc.com/p/s/breakout-session-4-male-breast-cancer-459
https://aonn.digitellinc.com/p/s/visit-the-exhibit-and-poster-hall-464
https://aonn.digitellinc.com/p/s/product-theater-3-cabometyx-r-clinical-management-of-advanced-rcc-and-hcc-non-ce-presentation-by-exelixis-469
https://aonn.digitellinc.com/p/s/product-theater-4-treatment-of-patients-in-newly-diagnosed-multiple-myeloma-patient-adherence-and-dose-modifications-in-response-to-adverse-events-non-ce-presentation-by-bristol-myers-squibb-474
https://aonn.digitellinc.com/p/s/product-theater-5-dosing-and-adverse-reaction-management-for-lenvima-r-non-ce-presented-by-eisai-479
https://aonn.digitellinc.com/p/s/industry-sponsored-session-identifying-appropriate-patients-for-ninlaro-r-ixazomib-an-oral-treatment-for-patients-with-multiple-myeloma-non-ce-presentation-by-takeda-489
https://aonn.digitellinc.com/p/s/general-session-7-biosimilars-494
https://aonn.digitellinc.com/p/s/visit-the-exhibit-and-poster-hall-499
https://aonn.digitellinc.com/p/s/product-theater-6-trodelvy-r-sacituzumab-govitecan-hziy-practical-considerations-and-patient-counseling-information-non-ce-presentation-by-immunomedics-504
https://aonn.digitellinc.com/p/s/product-theater-7-insights-on-managing-patients-with-cll-and-mcl-on-a-selective-btk-inhibitor-therapy-non-ce-presentation-by-astrazeneca-509
https://aonn.digitellinc.com/p/s/industry-sponsored-session-extensive-stage-sclc-unresectable-stage-iii-nsclc-and-metastatic-egfr-mutation-positive-nsclc-non-ce-presentation-by-astrazeneca-514
https://aonn.digitellinc.com/p/s/general-session-8-policy-and-advocacy-session-and-the-effects-of-covid-19-519
https://aonn.digitellinc.com/p/s/breakout-session-5-aonn-plus-poster-winner-presentations-categories-v-vii-524
https://aonn.digitellinc.com/p/s/breakout-session-6-research-session-role-of-navigators-in-accruing-for-clinical-trials-529
https://aonn.digitellinc.com/p/s/breakout-session-7-navigating-unknown-primary-cancer-534
https://aonn.digitellinc.com/p/s/breakout-session-8-value-based-care-and-alternative-payment-models-an-overview-539
https://aonn.digitellinc.com/p/s/visit-the-exhibit-and-poster-hall-544
https://aonn.digitellinc.com/p/s/product-theater-8-overview-of-immune-related-adverse-events-caused-by-immune-checkpoint-inhibitors-presentation-by-bristol-myers-squibb-549
https://aonn.digitellinc.com/p/s/product-theater-9-considerations-when-counseling-your-patients-about-darzalex-faspro-non-ce-presentation-by-janssen-554
https://aonn.digitellinc.com/p/s/industry-sponsored-session-treating-patients-with-advanced-prostate-cancer-metastatic-and-non-metastatic-pc-non-ce-presentation-by-janssen-559
https://aonn.digitellinc.com/p/s/industry-sponsored-session-insights-on-bone-complications-from-solid-tumor-bone-metastases-and-multiple-myeloma-non-ce-presentation-by-amgen-564
https://aonn.digitellinc.com/p/s/general-session-9-developing-and-sustaining-patient-navigation-programs-in-low-and-middle-income-countries-lmic-an-introduction-to-the-american-cancer-societys-building-expertise-advocacy-and-capacity-569
https://aonn.digitellinc.com/p/s/general-session-10-conflict-with-colleagues-in-oncology-care-574
https://aonn.digitellinc.com/p/s/general-session-11-prehab-and-rehab-for-oncology-patients-579
https://aonn.digitellinc.com/p/s/general-session-12-cancer-services-inc-584
https://aonn.digitellinc.com/p/s/general-session-13-vaping-589
https://aonn.digitellinc.com/p/s/cook-a-long-with-new-orleans-chef-amy-sins-non-ce-614
https://aonn.digitellinc.com/p/s/networking-with-your-peers-624
https://aonn.digitellinc.com/p/s/networking-with-your-peers-632
https://aonn.digitellinc.com/p/s/aonn-plus-networking-event-641
https://aonn.digitellinc.com/p/cf/aonn-plus-midyear-2021-virtual-conference-646
https://aonn.digitellinc.com/p/s/preconference-workshop-prehabrehab-661
https://aonn.digitellinc.com/p/s/preconference-workshop-the-nuts-and-bolts-of-building-a-navigation-program-666
https://aonn.digitellinc.com/p/s/general-session-1-smoking-cessation-671
https://aonn.digitellinc.com/p/s/general-session-2-making-a-business-case-for-financial-navigation-676
https://aonn.digitellinc.com/p/s/general-session-3-leveraging-technology-to-enhance-navigator-workflow-and-metrics-collection-681
https://aonn.digitellinc.com/p/s/general-session-4-taking-your-financial-navigation-to-the-next-level-686
https://aonn.digitellinc.com/p/s/general-session-5-geriatric-oncology-691
https://aonn.digitellinc.com/p/s/attendee-networking-session-696
https://aonn.digitellinc.com/p/s/exhibit-hall-open-701
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-bristol-myers-squibb-treatment-of-patients-in-newly-diagnosed-multiple-myeloma-patient-adherence-and-dose-modifications-in-response-to-adverse-events-706
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-exelixis-rcc-app-clinical-management-of-1l-advanced-rcc-patients-on-cabometyx-r-plus-opdivo-r-711
https://aonn.digitellinc.com/p/s/general-session-6-tumor-board-format-you-cant-make-this-stuff-up-716
https://aonn.digitellinc.com/p/s/breakout-session-1-caring-for-the-caregiver-721
https://aonn.digitellinc.com/p/s/breakout-session-2-screening-in-the-covid-era-726
https://aonn.digitellinc.com/p/s/breakout-session-3-prepping-your-professional-image-731
https://aonn.digitellinc.com/p/s/breakout-session-4-lack-of-support-for-patients-living-with-chronicmetastatic-disease-736
https://aonn.digitellinc.com/p/s/exhibit-hall-open-741
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-regeneron-harnessing-the-power-of-immunity-746
https://aonn.digitellinc.com/p/s/general-session-7-understanding-the-needs-of-the-aya-population-751
https://aonn.digitellinc.com/p/s/exhibit-hall-open-756
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-incyte-intervening-with-jakafi-r-ruxolitinib-to-achieve-durable-count-control-real-world-patient-case-discussion-focus-on-adults-with-polycythemia-vera-who-h-761
https://aonn.digitellinc.com/p/s/breakout-session-5-caring-for-the-caregiver-766
https://aonn.digitellinc.com/p/s/breakout-session-6-screening-in-the-covid-era-771
https://aonn.digitellinc.com/p/s/breakout-session-7-prepping-your-professional-image-776
https://aonn.digitellinc.com/p/s/breakout-session-8-lack-of-support-for-patients-living-with-chronicmetastatic-disease-781
https://aonn.digitellinc.com/p/s/exhibit-hall-open-786
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-lilly-a-cdk4-and-6-inhibitor-with-overall-survival-data-791
https://aonn.digitellinc.com/p/s/dying-is-not-giving-up-796
https://aonn.digitellinc.com/p/s/attendee-networking-session-801
https://aonn.digitellinc.com/p/s/general-session-8-end-of-life-session-806
https://aonn.digitellinc.com/p/s/general-session-9-powerful-conversations-with-your-oncology-colleagues-811
https://aonn.digitellinc.com/p/s/closing-remarks-816
https://aonn.digitellinc.com/p/s/industry-sponsored-session-presentation-by-janssen-erleada-r-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-non-metastatic-castration-resistant-prostate-c-823
https://aonn.digitellinc.com/p/s/opening-remarks-841
https://aonn.digitellinc.com/p/cf/aonn-plus-annual-2021-virtual-conference-847
https://aonn.digitellinc.com/p/s/preconference-workshop-nutrition-in-cancer-care-850
https://aonn.digitellinc.com/p/s/preconference-workshop-all-the-things-you-wish-you-knewabcs-to-start-a-navigation-program-855
https://aonn.digitellinc.com/p/s/preconference-workshop-palliative-care-what-navigators-need-to-know-860
https://aonn.digitellinc.com/p/s/preconference-workshop-l-survivorship-865
https://aonn.digitellinc.com/p/s/industry-sponsored-session-considerations-for-the-treatment-of-patients-with-lung-cancer-resectable-nsclc-and-unresectable-stage-iii-nsclc-presented-by-astrazeneca-870
https://aonn.digitellinc.com/p/s/welcome-opening-remarks-and-awards-875
https://aonn.digitellinc.com/p/s/general-session-1-genetics-and-genomics-880
https://aonn.digitellinc.com/p/s/industry-sponsored-session-what-you-can-do-today-for-your-kras-g12c-mutated-nsclc-patients-presented-by-amgen-885
https://aonn.digitellinc.com/p/s/general-session-2-technology-in-cancer-care-895
https://aonn.digitellinc.com/p/s/industry-sponsored-session-a-combination-treatment-for-patients-with-advanced-renal-cell-carcinoma-presented-by-exelixis-900
https://aonn.digitellinc.com/p/s/general-session-3-policy-and-advocacy-screening-905
https://aonn.digitellinc.com/p/s/general-session-4-precision-medicine-910
https://aonn.digitellinc.com/p/s/industry-sponsored-session-a-treatment-option-for-patients-with-certain-types-of-advanced-endometrial-carcinoma-presented-by-eisai-915
https://aonn.digitellinc.com/p/s/cape-programs-920
https://aonn.digitellinc.com/p/s/industry-sponsored-session-urgent-treatment-of-early-onset-severe-toxicity-of-5-fu-or-capecitabine-presented-by-wellstat-therapeutics-925
https://aonn.digitellinc.com/p/s/keynote-session-ending-cervical-cancer-is-within-our-reach-930
https://aonn.digitellinc.com/p/s/industry-sponsored-session-educate-your-patients-on-imbruvica-r-ibrutinib-treatment-presented-by-pharmacyclics-llc-an-abbvie-company-and-janssen-biotech-inc-935
https://aonn.digitellinc.com/p/s/industry-sponsored-session-tecentriq-first-fda-approved-adjuvant-cancer-immunotherapy-in-nsclc-presented-by-genentech-940
https://aonn.digitellinc.com/p/s/exhibit-hall-open-945
https://aonn.digitellinc.com/p/s/industry-sponsored-session-advances-in-targeted-therapy-for-cll-and-aml-efficacy-and-practical-management-of-bcl-2-inhibitors-presented-by-abbvie-950
https://aonn.digitellinc.com/p/s/general-session-5-chronic-disease-and-complex-care-navigation-management-955
https://aonn.digitellinc.com/p/s/breakout-session-1-fertility-960
https://aonn.digitellinc.com/p/s/breakout-session-2-cold-capscryotherapy-965
https://aonn.digitellinc.com/p/s/breakout-session-3-navigation-certification-overview-value-and-preparation-970
https://aonn.digitellinc.com/p/s/breakout-session-4-hematologic-malignancies-975
https://aonn.digitellinc.com/p/s/industry-sponsored-session-explore-data-for-an-fda-approved-treatment-option-in-hr-plus-her2-breast-cancer-in-certain-adjuvant-or-metastatic-settings-presented-by-lilly-pp-al-us-2989-c-lillyusa-llc-20-985
https://aonn.digitellinc.com/p/s/exhibit-hall-open-990
https://aonn.digitellinc.com/p/s/industry-sponsored-session-er-targeted-cerianna-pet-identifying-patients-that-can-benefit-from-cerianna-presented-by-ge-healthcare-1000
https://aonn.digitellinc.com/p/s/general-session-6caution-metrics-can-be-addicting-1005
https://aonn.digitellinc.com/p/s/industry-sponsored-session-cosela-a-novel-myeloprotection-therapy-presented-by-g1-therapeutics-1015
https://aonn.digitellinc.com/p/s/exhibit-hall-open-1020
https://aonn.digitellinc.com/p/s/industry-sponsored-session-evolving-cll-treatment-paradigms-exploring-chemo-free-regimens-with-a-fixed-treatment-duration-presented-by-genentech-1025
https://aonn.digitellinc.com/p/s/general-session-7-acuity-1030
https://aonn.digitellinc.com/p/s/breakout-session-1-fertility-1035
https://aonn.digitellinc.com/p/s/breakout-session-2-cold-capscryotherapy-1040
https://aonn.digitellinc.com/p/s/breakout-session-3-navigation-certification-overview-value-and-preparation-1045
https://aonn.digitellinc.com/p/s/breakout-session-4-hematology-1050
https://aonn.digitellinc.com/p/s/industry-sponsored-session-clinical-cases-in-polycythemia-vera-when-to-intervene-with-jakafi-r-ruxolitinib-focus-on-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hydroxyurea-present-1055
https://aonn.digitellinc.com/p/s/industry-sponsored-session-a-treatment-option-for-patients-with-myelodysplastic-syndromes-presented-by-bristol-myers-squibb-1060
https://aonn.digitellinc.com/p/s/exhibit-hall-open-1065
https://aonn.digitellinc.com/p/s/industry-sponsored-session-janssen-oncologys-shared-decision-making-strategies-presented-by-janssen-1070
https://aonn.digitellinc.com/p/s/attendee-networking-1075
https://aonn.digitellinc.com/p/s/aonn-plus-poster-awards-presentation-1080
https://aonn.digitellinc.com/p/s/general-session-8-professional-oncology-navigation-taskforce-standards-1085
https://aonn.digitellinc.com/p/s/general-session-9-technology-innovation-integration-to-address-underserved-disparate-patient-populations-1090
https://aonn.digitellinc.com/p/s/aonn-plus-leadership-live-1095
https://aonn.digitellinc.com/p/s/general-session-10-understanding-the-coc-1100
https://aonn.digitellinc.com/p/s/closing-remarks-1105
https://aonn.digitellinc.com/p/s/preconference-workshop-nutrition-in-cancer-care-1109
https://aonn.digitellinc.com/p/s/preconference-workshop-all-the-things-you-wish-you-knewabcs-to-start-a-navigation-program-1114
https://aonn.digitellinc.com/p/s/preconference-workshop-palliative-care-what-navigators-need-to-know-1119
https://aonn.digitellinc.com/p/s/preconference-workshop-l-survivorship-1124
https://aonn.digitellinc.com/p/s/concurrent-sessions-1125
https://aonn.digitellinc.com/p/s/concurrent-sessions-1130
https://aonn.digitellinc.com/p/s/concurrent-sessions-1135
https://aonn.digitellinc.com/p/s/concurrent-sessions-1140
https://aonn.digitellinc.com/p/s/concurrent-sessions-1145
https://aonn.digitellinc.com/p/s/concurrent-sessions-1150
https://aonn.digitellinc.com/p/s/concurrent-sessions-1155
https://aonn.digitellinc.com/p/s/concurrent-sessions-1160
https://aonn.digitellinc.com/p/s/concurrent-sessions-1165
https://aonn.digitellinc.com/p/s/attendee-networking-1168
https://aonn.digitellinc.com/p/cf/aonn-plus-midyear-2022-1172
https://aonn.digitellinc.com/p/s/aonn-plus-behind-the-scenes-with-your-aonn-plus-leaders-1177
https://aonn.digitellinc.com/p/s/preconference-workshop-1-understanding-the-needs-of-the-lgbtq-community-1182
https://aonn.digitellinc.com/p/s/discussing-anticancer-therapy-along-with-patient-monitoring-and-management-of-adverse-events-presentation-by-merck-1192
https://aonn.digitellinc.com/p/s/welcome-and-opening-remarks-1197
https://aonn.digitellinc.com/p/s/general-session-1-indigenous-oncology-navigation-1202
https://aonn.digitellinc.com/p/s/general-session-2-aya-tumor-board-1207
https://aonn.digitellinc.com/p/s/general-session-3-navigating-global-patients-1212
https://aonn.digitellinc.com/p/s/enhancing-the-cll-patient-experience-from-diagnosis-to-treatment-with-personalized-education-in-partnership-with-pharmacylics-1217
https://aonn.digitellinc.com/p/s/importance-of-early-detection-in-lung-cancer-elevating-the-navigators-role-presentation-by-astrazeneca-1222
https://aonn.digitellinc.com/p/s/general-session-4-the-changing-landscape-of-oncology-navigation-1227
https://aonn.digitellinc.com/p/s/nurse-navigators-connecting-the-gaps-between-patient-obstacles-and-receiving-care-in-lung-cancer-presentation-by-astrazeneca-1232
https://aonn.digitellinc.com/p/s/exelixis-clinical-product-overview-for-advanced-practice-providers-presentation-by-exelixis-1237
https://aonn.digitellinc.com/p/s/general-session-5-oral-chemotherapy-1242
https://aonn.digitellinc.com/p/s/trodelvy-practical-considerations-and-patient-counseling-information-presentation-by-gilead-1247
https://aonn.digitellinc.com/p/s/erleada-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-presentation-by-janssen-1252
https://aonn.digitellinc.com/p/s/general-session-6-implementing-a-transportation-hub-a-holistic-approach-to-a-systemic-problem-1257
https://aonn.digitellinc.com/p/s/explore-data-for-an-fda-approved-treatment-option-in-hr-plus-her2-breast-cancer-in-certain-adjuvant-or-metastatic-settings-presentation-by-lilly-oncology-1262
https://aonn.digitellinc.com/p/s/clinical-cases-in-polycythemia-vera-when-to-intervene-with-jakafi-r-ruxolitinib-focus-on-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hydroxyurea-presentation-by-incyte-1267
https://aonn.digitellinc.com/p/s/general-session-7-leveraging-gu-navigation-in-urology-groups-1272
https://aonn.digitellinc.com/p/s/cosela-a-novel-myeloprotection-therapy-presentation-by-g1-therapeutics-1277
https://aonn.digitellinc.com/p/s/genomic-profiling-in-early-stage-breast-cancer-presentation-by-agendia-1282
https://aonn.digitellinc.com/p/s/networking-with-exhibitors-1287
https://aonn.digitellinc.com/p/s/breakout-session-1-new-to-navigation-1292
https://aonn.digitellinc.com/p/s/breakout-session-2-the-hope-more-spa-1297
https://aonn.digitellinc.com/p/s/the-facts-on-egfr-exon-20-insertion-mutations-presentation-by-janssen-1302
https://aonn.digitellinc.com/p/s/breakout-session-1-new-to-navigation-1312
https://aonn.digitellinc.com/p/s/breakout-session-2-the-hope-more-spa-1317
https://aonn.digitellinc.com/p/s/general-session-8-the-disco-app-a-patient-focused-tool-to-reduce-financial-toxicity-1322
https://aonn.digitellinc.com/p/s/general-session-9-self-care-and-resiliency-1327
https://aonn.digitellinc.com/p/s/closing-remarks-1332
https://aonn.digitellinc.com/live/27/package/aonn-plus-midyear-2022-event-1337/
https://aonn.digitellinc.com/p/s/networking-with-exhibitors-1339
https://aonn.digitellinc.com/p/s/networking-with-exhibitors-1340
https://aonn.digitellinc.com/p/s/bold-mentorship-academy-building-oncology-leadership-and-development-and-networking-session-1341
https://aonn.digitellinc.com/p/s/managing-oncolytics-in-breast-cancer-the-pivotal-role-of-nurse-navigators-1342
https://aonn.digitellinc.com/p/s/managing-oncolytics-in-breast-cancer-the-pivotal-role-of-nurse-navigators-1343
https://aonn.digitellinc.com/p/cf/aonn-plus-2022-annual-conference-1345
https://aonn.digitellinc.com/p/s/test-session-1346
https://aonn.digitellinc.com/p/s/aonn-plus-leadership-team-behind-the-scenes-1347
https://aonn.digitellinc.com/p/s/preconference-workshop-1-technology-and-innovation-1348
https://aonn.digitellinc.com/p/s/preconference-workshop-2-administration-1349
https://aonn.digitellinc.com/p/s/preconference-workshop-3-hpv-1350
https://aonn.digitellinc.com/p/s/opening-remarks-and-overview-1352
https://aonn.digitellinc.com/p/s/general-session-1-implicit-bias-1353
https://aonn.digitellinc.com/p/s/general-session-2-oncological-emergencies-or-guided-dying-when-end-term-hospice-patients-wind-up-in-er-1354
https://aonn.digitellinc.com/p/s/general-session-3-not-a-handout-paying-for-navigators-in-value-based-contracting-1355
https://aonn.digitellinc.com/p/s/dinner-next-day-2-management-of-myelodysplastic-syndromes-a-panel-event-presentation-by-bristol-myers-squibb-1356
https://aonn.digitellinc.com/p/s/general-session-4-building-the-case-for-navigation-1357
https://aonn.digitellinc.com/p/s/general-session-5-survivorship-program-1358
https://aonn.digitellinc.com/p/s/breakout-session-1-genetics-and-genomics-1359
https://aonn.digitellinc.com/p/s/breakout-session-2-collaborative-clinical-and-community-stakeholder-partnerships-in-navigation-programs-1360
https://aonn.digitellinc.com/p/s/breakout-session-3-integrative-modalities-1361
https://aonn.digitellinc.com/p/s/lunch-next-day-3-the-facts-on-egfr-exon-20-insertion-mutations-and-the-treatment-of-adult-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-exon-20-insertion-mutations-whose-1362
https://aonn.digitellinc.com/p/s/general-session-6-coc-updates-1363
https://aonn.digitellinc.com/p/s/exhibit-hall-open-poster-q-and-a-1364
https://aonn.digitellinc.com/p/s/product-theater-1-car-t-cell-therapy-the-science-and-the-patient-journey-presentation-by-bristol-myers-squibb-1365
https://aonn.digitellinc.com/p/s/product-theater-2-a-review-of-evidence-based-data-for-an-antibody-drug-conjugate-for-lamuc-presentation-by-seagen-1366
https://aonn.digitellinc.com/p/s/product-theater-3-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv-a-case-based-presentation-presentation-by-helsinn-1367
https://aonn.digitellinc.com/p/s/product-theater-4-exkivity-r-mobocertinib-the-first-and-only-oral-therapy-designed-to-target-egfr-exon20-insertion-plus-mnsclc-presentation-by-takeda-1368
https://aonn.digitellinc.com/p/s/dinner-next-day-4-evolving-cll-treatment-paradigms-exploring-chemo-free-regimens-with-a-fixed-treatment-duration-presentation-by-genentech-1369
https://aonn.digitellinc.com/p/s/poster-presentations-reception-1370
https://aonn.digitellinc.com/p/s/breakfast-next-day-5-nurse-navigators-connecting-the-gaps-between-patient-obstacles-and-receiving-care-in-lung-cancer-presentation-by-astrazeneca-1371
https://aonn.digitellinc.com/p/s/keynote-session-beat-the-odds-by-sandy-gennaro-1372
https://aonn.digitellinc.com/p/s/exhibit-hall-open-1373
https://aonn.digitellinc.com/p/s/product-theater-5-healthcare-disparities-and-treatment-impact-for-multiple-myeloma-presentation-by-janssen-1374
https://aonn.digitellinc.com/p/s/product-theater-6-learn-more-about-an-fda-approved-treatment-for-metastatic-triple-negative-breast-cancer-presentation-by-gilead-1375
https://aonn.digitellinc.com/p/s/product-theater-7-a-collaborative-approach-to-deciding-when-to-intervene-with-jakafi-r-ruxolitinib-for-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hydroxyurea-presentation-by-incy-1376
https://aonn.digitellinc.com/p/s/product-theater-8-explore-data-for-an-fda-approved-treatment-option-in-hr-plus-her2-breast-cancer-in-certain-adjuvant-or-metastatic-settingspp-al-us-2989-c-lilly-usa-llc-2021-all-rights-reservedpresen-1377
https://aonn.digitellinc.com/p/s/lunch-breakout-session-4-genetics-and-genomics-1378
https://aonn.digitellinc.com/p/s/lunch-breakout-session-5-collaborative-clinical-and-community-stakeholder-partnerships-in-navigation-programs-1379
https://aonn.digitellinc.com/p/s/lunch-breakout-session-6-integrative-modalities-1380
https://aonn.digitellinc.com/p/s/exhbit-hall-open-1381
https://aonn.digitellinc.com/p/s/product-theater-9-whats-next-for-patients-with-relapsed-or-refractory-multiple-myeloma-after-multiple-lines-of-therapy-presentation-by-janssen-1382
https://aonn.digitellinc.com/p/s/product-theater-10-cosela-a-novel-myeloprotection-agent-presentation-by-g1-therapeutics-1383
https://aonn.digitellinc.com/p/s/product-theater-11-please-join-us-to-learn-about-a-treatment-option-for-advanced-nsclc-and-two-types-of-advanced-skin-cancers-presentation-by-regeneron-1384
https://aonn.digitellinc.com/p/s/product-theater-12-exelixis-clinical-product-overview-for-advanced-practice-providers-presentation-by-exelixis-1385
https://aonn.digitellinc.com/p/s/general-session-7-dealing-with-grief-1386
https://aonn.digitellinc.com/p/s/dinner-next-day-7-survivorship-care-planning-presentation-by-bristol-myers-squibb-1387
https://aonn.digitellinc.com/p/s/aonn-plus-celebration-with-guest-speaker-maimah-karmo-of-tigerlily-foundation-1388
https://aonn.digitellinc.com/p/s/general-session-8-navigation-acuity-project-the-art-of-lessons-learned-1389
https://aonn.digitellinc.com/p/s/general-session-9-designing-and-implementing-a-navigation-program-database-to-track-patient-care-delivery-and-report-metrics-1390
https://aonn.digitellinc.com/p/s/lunch-general-session-10-cancer-equity-and-inclusion-navigation-promoting-dei-in-cancer-1391
https://aonn.digitellinc.com/p/s/general-session-11-becoming-the-story-the-power-of-prehab-1392
https://aonn.digitellinc.com/p/s/closing-remarks-1394
https://aonn.digitellinc.com/p/s/general-session-12-caring-for-the-caregiver-1395